TME Pharma NV 2024 AR2
The report outlines TME Pharma N.V.'s financial and operational performance for the fiscal year 2024. Key highlights include the generation of unprecedented survival data from the GLORIA Phase 1/2 study of its lead cancer drug candidate, NOX-A12, in glioblastoma patients. Additionally, the US FDA granted Fast Track Designation for NOX-A12 in combination with radiotherapy and bevacizumab. The company also advanced its second clinical-stage asset, NOX-E36, in ophthalmology through collaboration with the Singapore Eye Research Institute. Financially, the company successfully raised €7.6 million in gross cash and ended its convertible bond financing program by redeeming all outstanding bonds.
Company: TME Pharma NV
Sector: Health Care
Country: Germany
Year: 2024
Type: AR2
Pages: 143
TME Pharma NV
Annual Report
The report outlines TME Pharma N.V.'s financial and operational performance for the fiscal year 2024. Key highlights include the generation of unprecedented survival data from the GLORIA Phase 1/2 study of its lead cancer drug candidate, NOX-A12, in glioblastoma patients. Additionally, the US FDA granted Fast Track Designation for NOX-A12 in combination with radiotherapy and bevacizumab. The company also advanced its second clinical-stage asset, NOX-E36, in ophthalmology through collaboration with the Singapore Eye Research Institute. Financially, the company successfully raised €7.6 million in gross cash and ended its convertible bond financing program by redeeming all outstanding bonds.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Employees